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(i) and 4-page (ii) formats; staff preferred 4-page (ii) and 2-page
(i) formats. Using this, we selected version (ii), 4-page format,
the common preference of both groups. Survey developers
should incorporate end-users to provide insight into format pref-
erences and cognitive processing.
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THE ROLE OF ANTIPARKINSONIAN AGENTS IN SELF-
REPORTED COGNITIVE IMPAIRMENT AND AKATHISIA
DURING THE LONG-TERM TREATMENT OF SCHIZOPHRENIA
Ascher-Svanum H, Zhu B, Faries D, Jiang Q
Eli Lilly and Company, Indianapolis, IN, USA
OBJECTIVES: In the treatment of schizophrenia, antiparkin-
sonian agents (APKs) are customarily used to counteract drug-
induced reversible movement disorders such as extrapyramidal
symptoms in order to facilitate adherence to antipsychotic regi-
mens. Unfortunately, in addition to beneﬁcial effects, APKs were
shown to cause other adverse effects such as cognitive impair-
ment. This study prospectively examined the role of APKs in self-
reported medication-related cognitive impairment and akathisia
(subjective or objective restlessness) among patients treated over
a 3-year period in usual care with olanzapine or risperidone.
METHODS: Using data from a 3-year observational study of
schizophrenia, we included olanzapine (N = 372) and risperidone
(N = 229) treated patients who continued on index medication
for at least 1-year post enrollment. Medication use was based 
on medical records. Self-reported medication-related cognitive
impairment and akathisia were assessed with validated instru-
ments. Analysis included mixed models adjusted for covariates.
RESULTS: Utilization rates of APKs were almost twice as high
among risperidone than olanzapine-treated patients (p = 0.001).
When not receiving APKs, akathisia was signiﬁcantly worse for
risperidone than olanzapine-treated patients, and rates of
akathisia were comparable when receiving APKs. However,
when receiving APKs, risperidone-treated patients reported sig-
niﬁcant increases in cognitive impairment compared to olanzap-
ine-treated patients (p = 0.0198). CONCLUSIONS: In this
naturalistic 3-year study, freedom from adjunctive antiparkin-
sonian agents was associated with worse akathsia for risperidone
than olanzapine-treated patients. Moreover, use of antiparkin-
sonian agents was linked to worsening of self-reported cognitive
impairment for risperidone but not for olanzapine-treated
patients. Further studies are needed to examine this 
phenomenon.
PMH51
PMH52
IMPROVEMENT IN QUALITY-OF-LIFE WITH RISPERIDONE
AUGMENTATION IN TREATMENT-RESISTANT DEPRESSION
Walling D1, Rupnow M2, Canuso C2, Gharabawi G2,Turkoz I2,
Rapaport M3
1CNS Network, Garden Grove, CA, USA; 2Janssen Pharmaceutica
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OBJECTIVE: To evaluate the effect of adjunctive risperidone
treatment on quality of life in patients with treatment-resistant
depression (TRD). METHODS: Data from the open-label treat-
ment phase (4–6 weeks) of an international study designed to
evaluate the efﬁcacy, safety, and maintenance effect of risperi-
done augmentation to SSRI-treatment in TRD. Quality of life
was evaluated using the short form of Quality-of-Life Enjoyment
and Satisfaction Questionnaire (Q-LES-Q). Change in Q-LES-Q
from baseline was analyzed by paired t-test. Correlation analy-
ses between MADRS and Q-LES-Q change scores were per-
formed using Pearson method. RESULTS: This analysis included
386 subjects, mean age 47.1. Baseline and endpoint mean (SD)
Q-LES-Q scores were 42.8 (14.6) and 56.0 (18.6), indicating 
an improvement of 13.2 with risperidone augmentation (P <
0.0001). Signiﬁcant improvements were observed as early as day
7 (P < 0.0001). Q-LES-Q item 15, medication satisfaction, was
rated as good or very good by 61% of subjects. Correlation
between Q-LES-Q and MADRS total change scores at endpoint
was -0.6. CONCLUSIONS: These ﬁndings suggest that aug-
mentation with risperidone rapidly and signiﬁcantly improves
quality of life in TRD patients. Consistent with previous work,
the correlation between Q-LES-Q and MADRS indicate a mean-
ingful relationship between quality of life improvement and
symptom relief.
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OBJECTIVE: Investigate the effect of atypical antipsychotics
(quetiapine, risperidone, and olanzapine) in combination with a
mood stabilizer on hospitalization rates for bipolar disorder.
METHOD: From the MEDSTAT MarketScan© medical claims
database (1998–2001), 977 individuals were identiﬁed who had
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a diagnosis of bipolar disorder and received combination therapy
with an atypical antipsychotic and a mood stabilizer. A 2-stage
sample selection model controlled for differences between indi-
viduals receiving antipsychotics and factors that may impact 
the probability of hospitalization, i.e. demographics, bipolar
type, disease severity, comorbidities, mood stabilizer used, and
antipsychotic used. RESULTS: Individuals most likely to be hos-
pitalized were those diagnosed as manic or bipolar depressed, or
were receiving divalproex sodium or gabapentin. In pair-wise
comparisons, hospitalization in the year following the start of
combination antipsychotic therapy was 44% less likely for those
receiving quetiapine vs olanzapine (P = 0.0354). There was no
signiﬁcant difference in the likelihood of hospitalization for 
the quetiapine group compared to the risperidone group (P =
0.5826). CONCLUSIONS: In patients with bipolar disorder
receiving a mood stabilizer plus an atypical antipsychotic, the
probability of hospitalization with quetiapine was signiﬁcantly
lower than with olanzapine, and similar to risperidone. These
ﬁndings are relevant to prescription choices among atypical
antipsychotics, for maximizing patient beneﬁt and minimizing
the burden of disease.
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OBJECTIVE: To assess indirect costs of work loss associated
with bipolar disorder and major (unipolar) depression.
METHOD: From MEDSTAT’s employer-based MarketScan©
database for year 2000, workers (mean age 42 ± 9) with a
primary ICD9-CM diagnosis of bipolar disorder (N = 740),
major depression (N = 6314), and one-to-one matched controls
with no psychiatric diagnosis were identiﬁed. Work loss para-
meters were absence hours and payments for short-term disabil-
ity and worker compensation. RESULTS: Mean annual absence
hours were 55 (±49) for the bipolar group vs 21 (±27) for con-
trols (P = 0.009), and 53 (±154) for the unipolar depression
group vs 24 (±48) for controls (P < 0.0001). Mean short-term
disability payments were $1231 (±3424) for the bipolar group
vs $131 (±967) for controls (P < 0.0001), and $741 (±2873) for
the unipolar depression group vs $178 (±1309) for controls (P <
0.0001). Mean worker compensation payments were $554
(±4231) for the bipolar group vs $228 (±2289) for controls (P =
0.15), and $518 (±4814) for the unipolar depression group 
vs $220 (±2449) for controls (P = 0.0001). CONCLUSIONS:
Bipolar disorder and major (unipolar) depression signiﬁcantly
increased work loss. Patients with bipolar disorder may exhaust
their sick leave and go onto short-term disability more frequently
than those with unipolar depression.
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OBJECTIVE: The Child Health Illness Proﬁle-Child Edition
(CHIP-CE) instrument is a psychometrically sound pediatric
quality of life measure that works well in diverse ethnic and
racial populations. Although the CHIP-CE has been used in a
variety of populations, no known studies have used this instru-
ment to evaluate the quality of life of children with Attention
Deﬁcit/Hyperactivity Disorder (ADHD). Our objective was to
evaluate the quality of life of children using the CHIP-CE in a
population of ADHD patients commonly treated with medica-
tions. METHODS: The CHIP-CE is a 76-item, parent-report
questionnaire that assesses multiple domains of children’s health-
related quality of life including: satisfaction (with self and
health), comfort (emotional and physical symptoms and limita-
tions), resilience (positive activities that promote health), risk
avoidance (risky behavior that inﬂuences future health), and
achievement (of social expectations in school and with peers).
Standard scores (mean = 50, SD = 10) are established. One
hundred thirty people in the United Kingdom (UK) were screened
to ﬁnd 83 eligible parents of children with ADHD to participate
in a survey including the CHIP-CE questionnaire and an ADHD
symptom frequency measure, the ADHD-RS. RESULTS: The
total mean ADHD-RS score (37.2) in the sample was high and
comparable to patients in drug trails (the normative non-ADHD
score ranges from 7.4 to 12.5). The children of the parents rated
had a mean age of 12.6. Seventy-two and three-tenths percent
were currently being treated with stimulants and 97.6% were
currently receiving therapy of either stimulants or psychother-
apy. Children in the sample had considerable impairment in all
5 domains of the CHIP-CE, in particular the risk avoidance
(25.2), achievement (29.1), and satisfaction (28.7) domains.
CONCLUSION: The CHIP-CE assessment shows signiﬁcant
quality of life impairment in this sample of children with ADHD,
despite 70% of the patients being currently treated with 
stimulant medication.
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OBJECTIVE: Mental health disorders among children and ado-
lescents do not have sufﬁcient attention. The purpose of this
study was to assess direct health care costs and drug utilization
for students with mental health illnesses in School-Based Health
Centers (SBHC) and comparable schools. METHODS: Four
SBHC intervention and two comparable non-SBHC schools (dis-
tricts) in Ohio were selected for this study. A total of 1200 stu-
dents who were enrolled in Medicaid program and had at least
one mental illness diagnosis and received mental health medica-
tions were identiﬁed for this cohort. There were 850 students in
those schools with SBHCs, and 350 students in non-SBHCs. The
study period was from August 1997 to August 2002. Repeated
measures analysis of covariates (ANCOVA) was conducted to
assess the adjusted monthly total cost and the monthly mental
health service cost before and after the SBHC program.
RESULTS: The cohort involved 64.8% male, 40.7% African-
American, and average 9.8 (SD 2.65) years-old in September
2001. During the study period, average monthly total costs were
$221 (SD 692) before SBHC and $295 (SD 742) after SBHC.
The most frequently diagnosed mental illnesses for all students
were hyperkinetic syndrome of childhood, adjustment reaction,
disturbance of emotion/conduct, affective psychoses, neurotic
disorders, and speciﬁc delays in development. Frequently pre-
scribed medications were antihyperkinesis agents (4.3 Rx per
